FundedIQ
Biotechnology

Nucleome Therapeutics: Funding, Investors & Team (Oct 2026)

www.nucleome.com LinkedIn Headington, United Kingdom 11-50 employees
Biotechnology Genetics Therapeutics B2B
Total raised
$42.3M
Rounds
1
Latest
Series A
Oct 2022

Nucleome Therapeutics has raised $42.3M across 1 funding round on record, the most recent a Series A of $42.3M announced in Oct 2022.

That round is above the $8.1M median round size for Biotechnology companies tracked on FundedIQ over the last two years.

Nucleome Therapeutics Company Profile and Key Stats

Total funding raised
$42.3M
across 1 round on record
Funding rounds on record
1
Latest funding round
Series A
$42.3M in Oct 2022
Employees
11-50
reported band
Headquarters
Headington, United Kingdom

Latest funding round on record: Oct 2022.

Nucleome Therapeutics Funding Rounds

Date
Round
Amount
Series A
$42.3M

Nucleome Therapeutics Founders and Leadership Team

Name
Role
Contact
Danuta Jeziorska
CEO
—

No contact details are on record for this team yet.

Nucleome Therapeutics Funding Compared to Other Biotechnology Startups

Segment
Companies
Median round
4,185
$8.1M
5,343
$4.1M
8,523
$15M

Nucleome Therapeutics' latest round of $42.3M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.

Funded Startups Like Nucleome Therapeutics in Biotechnology and Headington

Companies Similar to Nucleome Therapeutics

R1 Therapeutics is a clinical‑stage biopharmaceutical company focused on discovering and developing new drug…

Series A $3.0M

The perfect package for any general surgical trainee or resident. Progress from beginner to advanced surgical…

Undisclosed round $9.3M

Argonaute RNA company research projects build on existing intellectual property.

Undisclosed round $1.8M

An innovative C elegans company that serves the biotech, nutrition, and other industries and fields of study…

Undisclosed round $1.8M

ViaNautis, previously known as SomaServe, was established in 2018 as a separate entity from UCL under the…

Undisclosed round $23.3M

Alchemab is harnessing the naturally protective power of patient antibodies to keep people free of…

Series A $33.6M

Biodexa Pharmaceuticals is an international specialty pharmaceutical company focused on oncology and other…

Undisclosed round $3.5M

Concert Bio helps businesses create optimal microbial communities.

Undisclosed round $130k

RQ Bio is a biotechnology company that develops long-acting monoclonal antibodies against seasonal influenza…

Series A $113M

N4 Pharma is a drug reformulation company focused on developing and out licensing new versions of existing…

Undisclosed round $3.6M

Laverock Therapeutics is working on developing a system for suppressing genes, which can be used to create…

Undisclosed round $3.0M

Oak hill bio is a clinical-stage rare disease therapeutics company developing life-changing medicines.

Series A $32.5M

Nucleome Therapeutics Funding FAQs

How much funding has Nucleome Therapeutics raised?

Nucleome Therapeutics has raised $42.3M across 1 round on record. The most recent is a Series A of $42.3M announced in Oct 2022.

When did Nucleome Therapeutics last raise funding?

Nucleome Therapeutics' most recent funding round on record is a Series A of $42.3M, announced in Oct 2022.

Who is the CEO of Nucleome Therapeutics?

Danuta Jeziorska is listed as CEO at Nucleome Therapeutics.

Where is Nucleome Therapeutics headquartered?

Nucleome Therapeutics is based in Headington, Oxfordshire, United Kingdom.

How many employees does Nucleome Therapeutics have?

Nucleome Therapeutics is in the 11-50 employee band.

How does Nucleome Therapeutics' funding compare to other Biotechnology startups?

Nucleome Therapeutics' latest round of $42.3M is above the $8.1M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.

About FundedIQ's Nucleome Therapeutics Funding Data

FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.

Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Nucleome Therapeutics is left off this page rather than filled in.

14-day free trial · Cancel anytime

Know who just raised. Then know who to reach.

Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.

Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.